Kudzu Compound Could Help Alcoholics Quit Drinking Nov 18, 2009
The company decided to continue the study after it acquired CV Therapeutics, which initiated the study, Kaiser said in an e-mail. The report by Diamond, professor emeritus of neurology, neuroscience, and cellular and molecular pharmacology at the University of California-San Francisco, and Li, former director of the National Institute on Alcohol Abuse and Alcoholism, appears in November's Alcoholism: Clinical & Environmental Research. (W-USA News, DC)
Stocks Stumble on Growth Worries Aug 18, 2009
Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009. In economic news Monday, the NAHB homebuilder index, which has been on an improving trend since hitting a record low 8 in January, rose to 18 in August from 17 in July. (BusinessWeek)
Gilead Sciences Announces Colorado Closures Aug 13, 2009
-based CV Therapeutics earlier this year. About half the Colorado employees were offered the opportunity to relocate to California. (ABC News -- Wire)
Cooley Corporate Stars Switching to Dewey Jul 8, 2009
4 billion acquisition of CV Therapeutics Inc. His recent big deals also included Brocade Communications Systems' $3 billion acquisition of Foundry Networks Inc. Reifschneider led Cooley's team in Qualcomm Inc.'s $891 settlement of patent litigation earlier this year. The three often had roles on each others' deals. (Law.com)
Business leaders keep eye on DC energy plans Jul 7, 2009
3Degrees Group: 100 percent carbon neutral, with offsets for business travel emissions Acterra: 100 percent carbon neutral, with photovoltaics Adobe Systems Inc.: Emissions 29 percent below 1999 levels in East and West Towers City of Morgan Hill: Lighting retrofit in three buildings to reduce emissions by 40 tons per year CV Therapeutics Inc.: Reduced emissions by about 450,000 pounds from 2006 Integrated Archive Systems: Carbon-neutral building Integrated Design Associations: Zero-carbon... (San Jose Business Journal, CA)
Report: Pharma deals in 1Q exceed all 2008 deals Apr 28, 2009
8 billion, including debt, and Gilead Sciences Inc. buying CV Therapeutics Inc. for $1. 4 billion. (Yahoo News -- Pharmaceutical Industry News)
Wall Street Merger Rainmakers Stay `Hopeful' in Worst Market in Six Years Apr 1, 2009
1 billion offer for CV Therapeutics Inc. and Agrium Inc.s play for CF Industries Holdings Inc., worth more than $3 billion. Sellers are pretty reluctant to sell themselves at these levels, said , head of M&A at Citigroup Inc.. (Bloomberg)
Gilead Sciences: High-Performing Pharmaceutical Mar 28, 2009
4 billion to buy CV Therapeutics, which develops drugs for cardiovascular diseases. Gilead's focus on hard-to-cure infectious diseases may also put it in a strong position compared with some other drugmakers. (BusinessWeek)
Locals on CV Therapeutics board face suit Mar 26, 2009
Triangle businessmen on CV Therapeutics board face suit over Gilead deal - Triangle Business Journal ... Triangle businessmen on CV Therapeutics board face suit over Gilead deal ... TBJ file photo Kenneth Lee is chairman of CV Therapeutics board and a partner at Hatteras Venture Partners. (Triangle Business Journal)
Astellas Abandons Hostile CV Therapeutics Bid After Higher Offer by Gilead Mar 16, 2009
Astellas Abandons Hostile Bid to Buy CV Therapeutics (Update1) - Bloomberg ... Astellas Abandons Hostile Bid to Buy CV Therapeutics (Update1) ... 1 billion bid for CV Therapeutics Inc. after the U.S. company agreed to a higher offer by a rival. (Bloomberg -- Asia)
Stock Preacher Issues Technical Trade Alerts on: BAC, C, CVTX, DNA, GE, GM Mar 14, 2009
Today's Trade Alerts include: Bank of America Corporation (NYSE: ), Citigroup, Inc. (NYSE: ), CV Therapeutics, Inc. (Nasdaq: ), Genentech Inc. (NYSE: ), General Electric Company (NYSE: ), General Motors Corporation (NYSE: ). Join the fastest growing investment community at. (PR Newswire)
Will Roche takeover preserve Genentech culture? Mar 14, 2009
4 billion offer announced Thursday for Palo Alto cardiovascular drugmaker CV Therapeutics by leading HIV drug developer Gilead Sciences Inc. of Foster City. Pharmaceutical heavyweights are rushing to build out their pipelines of new drugs while cutting costs to meet the challenges of a flailing economy and increasing price pressures. (San Francisco Chronicle)
Wall Street US stocks extend rally Mar 13, 2009
On Nasdaq, biopharmaceutical company Gilead Sciences said it will buy CV Therapeutics for about $US1. 4 billion, stepping in the middle of a hostile bid for CV from Japan's Astellas Pharma. (Sydney Morning Herald -- Business)
Astellas Hasn't Ruled Out Raising, Dropping Hostile CV Therapeutics Bid Mar 13, 2009
1 billion bid to buy CV Therapeutics Inc. after the company agreed to a higher offer from a rival ... Chief Executive Officer , 61, made the hostile bid for CV Therapeutics even after two rejections to bolster a thinning development pipeline and counter dwindling sales as existing medications lose patent protection ... Astellas is after the Ranexa chest-pain treatment of CV Therapeutics, which agreed yesterday to a $1. (Bloomberg -- Japan)
Dow back above 7,000 as stocks extend rally to third day Mar 13, 2009
8 billion, while Gilead Sciences agreed to buy CV Therapeutics for $1. 4 billion. (USA Today -- Money)
Gilead buys maker of heart drugs Mar 13, 2009
will pay $20 a share for CV Therapeutics of Palo Alto, Calif ... Gilead gains CV Therapeutics' chest pain drug Ranexa ... CV Therapeutics shares rose $5. (Boston Globe)
Gilead to buy CV Therapeutics for $1.4B Mar 13, 2009
Gilead to buy CV Therapeutics for $1 ... Gilead to buy CV Therapeutics for $1 ... Foster City-based Gilead (NASDAQ:GILD) and Palo Alto-based CV Therapeutics (NASDAQ:CVTX) said CV Therapeutics will become a wholly-owned subsidiary of Gilead. (San Jose Business Journal, CA)
Roche reaches agreement to buy Genentech for $47 billion Mar 13, 2009
In a smaller deal announced Thursday, Gilead Sciences said it would buy another California company, CV Therapeutics, for $20 a share or $1. 4 billion, gaining the rights to drugs for cardiovascular diseases. (International Herald Tribune -- Business)
CV Therapeutics Urges Shareholders to Ignore Astellas $1 Billion Cash Bid Feb 28, 2009
CV Therapeutics Urges Shareholders to Ignore Astellas Offer ... Thats the same price the board of Palo Alto, California-based CV Therapeutics, maker of the Ranexa chest-pain treatment, rejected as too low on Feb. 20 ... CV Therapeutics advised its shareholders to take no action at this time, the company said today in a statement. (Bloomberg -- Japan)
To The Point Feb 22, 2009
CV Therapeutics rejects buyout ... Meanwhile, CV Therapeutics () said its Q4 loss widened to 60 cents, missing views by 28 cents. (Investors Business Daily)
CV Therapeutics rejects Astellas bid again, reports $37M Q4 loss Feb 21, 2009
The proposal by Astellas of $16 a share was the same one proposed and rejected in November, CV Therapeutics said. Astellas sells Lexiscan, a drug developed by CV Therapeutics that increases blood flow. (San Jose Business Journal, CA)
Recession Doesn't Hold Back the Hottest Stocks Feb 17, 2009
CV Therapeutics, which is pinning most of its hopes on a proposed drug for heart pain, spurned the offer. In late January, Astellas renewed its $16-a-share offer. (Bloomberg -- Columnists)
